SCHEDULE: Genextra, Micheli, Renzulli Divest Quince Therapeutics Stake

Genextra S.p.A., Francesco Micheli, and Matteo Bruno Renzulli have reported 0% beneficial ownership in Quince Therapeutics, Inc., indicating a full divestment of their previously held stake.

Summary

• Genextra S.p.A., Francesco Micheli, and Matteo Bruno Renzulli (the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Quince Therapeutics, Inc.
• The filing indicates that as of July 7, 2025, the Reporting Persons beneficially own 0 shares of Quince Therapeutics, Inc. Common Stock, representing 0% of the class.
• This amendment signifies that the Reporting Persons no longer hold a reportable stake (i.e., less than 5%) in Quince Therapeutics, Inc.
• The filing was made jointly by Genextra S.p.A., Francesco Micheli (Chairman and CEO of Genextra S.p.A.), and Matteo Bruno Renzulli, all of Italian citizenship or organization.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a significant shareholder has fully divested their stake, which can be interpreted by the market as a lack of continued confidence in the company's prospects from that particular investor group.

Positives

• NA

Negatives

• The Reporting Persons, who previously held a reportable stake, have fully divested their ownership in Quince Therapeutics, Inc., now holding 0% of the common stock.

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Quince Therapeutics, Inc.'s future outlook.

Industry Context

This filing reflects a change in the shareholder base of Quince Therapeutics, Inc., with a previously significant holder divesting their entire stake. Such changes are common in the biotechnology and pharmaceutical sectors, where investor sentiment and strategic shifts can lead to adjustments in portfolio holdings.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The divestment by a previously significant shareholder could lead to questions about the company's long-term prospects or investor confidence, potentially influencing trading behavior.
• Company Management: Management may need to address the implications of a significant shareholder's exit, particularly if it signals broader concerns.

Key Dates

Keywords

Quince Therapeutics, Genextra S.p.A., Francesco Micheli, Matteo Bruno Renzulli, Schedule 13G, Beneficial Ownership, Divestment, Shareholder Change, Common Stock